Dec 6 (Reuters) – Regeneron said on Saturday its experimental cancer combination therapy was effective and showed disappearance of the disease in previously untreated patients with a type of blood cancer in the first part of a late-stage trial.

The trial, which enrolled 22 patients, studied safety and preliminary efficacy of the company’s therapy, odronextamab, in combination with chemotherapy in patients with Diffuse Large B-Cell Lymphoma or DLBCL.

Odronextamab belongs to a class of treatments called bispecific antibodies that are designed to attach to a cancer cell and an immune cell, bringing them together so that the body’s immune system can kill the cancer.

At the 160 mg dose of the combination, patients showed 100% complete response rate, the company said.

DLBCL is a fast-growing

See Full Page